News coverage about Covidien (NYSE:COV) has trended somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Covidien earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave media headlines about the healthcare company an impact score of 47.0442614028574 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media headlines that may have effected Accern Sentiment’s analysis:

Covidien (COV) remained flat at $$106.71 during trading on Tuesday. Covidien has a 12-month low of $65.97 and a 12-month high of $108.57.

In other news, Director Jeffrey Mandel sold 9,000 shares of Covidien stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $2.99, for a total transaction of $26,910.00. Over the last ninety days, insiders have sold 13,333 shares of company stock valued at $29,900.

WARNING: “Covidien (COV) Earning Somewhat Favorable Press Coverage, Analysis Finds” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://theolympiareport.com/2017/12/05/covidien-cov-earning-somewhat-favorable-press-coverage-analysis-finds.html.

Covidien Company Profile

Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company’s brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries.

Insider Buying and Selling by Quarter for Covidien (NYSE:COV)

Receive News & Ratings for Covidien Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covidien Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.